首页 > 抗体蛋白 > 抗体
Purified anti-human CD274 (B7-H1, PD-L1) Antibody
产品名称:
Purified anti-human CD274 (B7-H1, PD-L1) Antibody
产品类别:
抗体
产品编号:
329701
产品应用:
329701
[价格]
规格 价格 库存
25µg ¥ 708 1

产品详情

Product Details

Verified Reactivity
Human
Reported Reactivity
African Green, Baboon, Cynomolgus, Rhesus
Antibody Type
Monoclonal
Host Species
Mouse
Immunogen
Full length human PD-L1
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C.
Application

FC - Quality tested
IHC-P - Verified
Block - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.5 ?g per million cells in 100 ?l volume. For immunohistochemical staining on formalin-fixed paraffin-embedded tissue sections, the suggested use of this reagent is 5.0 - 10 ?g per ml. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

Clone 29E.2A3 is reported to recognize an epitope on PD-L1 within the PD-L1-CD80 binding region5.?Additional reported applications (for the relevant formats) include: blocking1-3 and immunohistochemical staining of acetone-fixed frozen sections1.?The Ultra-LEAF? purified antibody (Endotoxin < 0.01 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 329715, 329716, 329745 - 329748).?

It has been observed that clone 29E.2A3 is able to bind to Alexa Fluor? 700 antibody conjugates during multi-color immunofluorescent staining. This interaction can be resolved by sequentially staining with the 29E.2A3 antibody first and then followed by the?Alexa Fluor? 700?conjugate of interest.

Clone 29E.2A3 does not work in Western blot applications7.

Application References

(PubMed link indicates BioLegend citation)
  1. Brown J, et al. 2003. J. Immunol. 170:1257. (FC, IHC, Block)
  2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (Block)
  3. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (Block)
  4. Barsoum IB, et al. 2014. Cancer Res. 74:665. PubMed
  5. Haile, S et al. 2013. J. Immunol. 191:2829.
  6. RL M, et al. 2015. PNAS. 112:6506-6514. PubMed
  7. Mahoney KM, et al. 2015. Cancer Immunol. Res. 3:1308.
Product Citations
  1. Zhou B, et al. 2020. Theranostics. 10:6530. PubMed
  2. Zheng G, et al. 2021. Signal Transduct Target Ther. 6:236. PubMed
  3. Yonemitsu K, et al. 2022. Sci Rep. 12:12007. PubMed
  4. Barsoum I, et al. 2014. Cancer Res. 74:665. PubMed
  5. Hamanishi J, et al. 2015. J Clin Oncol. 101200/JCO2015623397. PubMed
  6. Komohara Y, et al. 2018. J Clin Exp Hematop. 58:152. PubMed
  7. Parackova Z, et al. 2020. Sci Rep. 0.759027778. PubMed
  8. Paterson K, et al. 2022. IEEE Open J Eng Med Biol. 3:86. PubMed
  9. Juttukonda LJ, et al. 2017. Cell Host Microbe. 22:531. PubMed
  10. Heesters BA, et al. 2021. J Exp Med. 218:. PubMed
  11. Hsu DC, et al. 2018. Clin Infect Dis. 67:437. PubMed
  12. Nolan E, et al. 2017. Sci Transl Med. 9:eaal4925. PubMed
  13. Hartley GP, et al. 2018. Cancer Immunol Res. 6:1260. PubMed
  14. Lee SWL, et al. 2018. Front Immunol. 8:1064. PubMed
  15. Zeller AN, et al. 2021. Eur Cell Mater. 41:603. PubMed
  16. Agrawal N, et al. 2018. Front Immunol. 2.053472222. PubMed
  17. Li C, et al. 2016. Nat Commun. 7:12632. PubMed
  18. Perdigoto AL, et al. 2022. JCI Insight. 7:. PubMed
  19. Kim DH, et al. 2019. Exp Mol Med. 51:94. PubMed
  20. Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed
  21. Baruah P, et al. 2019. Front Immunol. 10:1644. PubMed
  22. Schwabenland M, et al. 2021. Immunity. . PubMed
  23. Salvany‐Celades M et al. 2019. Cell Rep. 27(9):2537-2547 . PubMed
  24. Acheampong E, et al. 2019. Cancers (Basel). 11. PubMed
  25. Hang Q, et al. 2020. Zhongguo Fei Ai Za Zhi. 1.539583333. PubMed
  26. Saber MM, et al. 2022. Antibodies (Basel). 11:. PubMed
  27. Kim MH, et al. 2018. Cancer Immunol Res. 0.427083333. PubMed
  28. Kennedy-Darling J, et al. 2021. Eur J Immunol. 51:1262. PubMed
  29. Garcia de Moura R, et al. 2021. Front Immunol. 12:632667. PubMed
  30. Wang Y, et al. 2019. Sci Rep. 9:566. PubMed
  31. Burr ML, et al. 2017. Nature. 549:101. PubMed
  32. Janse van Rensburg HJ, et al. 2018. Cancer Res. 78:1457. PubMed
  33. Enyindah-Asonye G, et al. 2019. Front Immunol. 10:511. PubMed
  34. Lavin Y et al. 2017. Cell. 169(4):750-765 . PubMed
  35. Hwang HJ, et al. 2021. Immun Inflamm Dis. 9:274. PubMed
  36. Bouchard G, et al. 2022. Cancer Res. 82:648. PubMed
RRID
AB_940370 (BioLegend Cat. No. 329701) AB_940372 (BioLegend Cat. No. 329702)

Antigen Details

Distribution

T cells, B cells, NK cells, monocytes/macrophages, granulocytes and dendritic cells

Function
CD274 is involved in the costimulatory signal, essential for T lymphocyte proliferation and production of IL-10 and IFN-γ, in an IL-2-dependent and a PD-1-CD1-independent manner. Its interaction with PD-1-CD1 inhibits T-cell proliferation and cytokine production.
Ligand/Receptor
PD-1 (PDCD1)
Cell Type
B cells, Dendritic cells, Fibroblasts, Granulocytes, Macrophages, Monocytes, NK cells, T cells
Biology Area
Cancer Biomarkers, Costimulatory Molecules, Immunology
Molecular Family
Adhesion Molecules, CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Sharpe A, et al. 2007. Nat. Immunol. 8:239.

Gene ID
29126 View all products for this Gene ID
UniProt
View information about CD274 on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线